Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

July 23, 2019

Study Completion Date

February 1, 2020

Conditions
Ischemic Stroke
Interventions
DRUG

Tenecteplase

Tenecteplase 0.25mg/kg and 0.4mg/kg are being used

Trial Locations (28)

1001

Auckland Hospital, Grafton

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

2170

Liverpool Hospital, Liverpool

2200

Bankstown-Lidcombe Hospital, Bankstown

2250

Gosford Hospital, Gosford

2560

Campbelltown Hospital, Campbelltown

2605

Royal North Shore Hospital, St Leonards

2640

Albury Hospital, Albury

3004

Alfred Hospital, Melbourne

3021

Western Heath, St Albans

3050

Royal Melbourne Hospital, Melbourne

3128

Box Hill Hospital, Box Hill

3168

Monash Medical Centre, Clayton

3280

South West Healthcare, Warrnambool

3353

Ballarat Health Services, Ballarat

3630

Goulburn Valley Health, Shepparton

3677

North East Health Wangaratta, Wangaratta

3844

Latrobe Regional Hospital, Traralgon

4102

Princess Alexandra Hospital, Woolloongabba

4560

Sunshine Coast University Hospital, Nambour

5000

Royal Adelaide Hospital, Adelaide

5112

Lyell McEwin Hospital, Elizabeth Vale

8011

Christchurch Hospital, Christchurch

Unknown

John Hunter Hospital, Newcastle

Royal Brisbane & Women's Hospital, Brisbane

Gold Coast University Hospital, Gold Coast

Austin Hospital, Heidelberg

Sponsors
All Listed Sponsors
collaborator

The Florey Institute of Neuroscience and Mental Health

OTHER

lead

Neuroscience Trials Australia

OTHER

NCT03340493 - Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2) | Biotech Hunter | Biotech Hunter